CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care

Anesthesia and Analgesia

Volumn 113, Issue 1, 2011, Pages 48-54

  Stamer, Ulrike M ^a   Lee, Eun Hae ^a   Rauers, Neele I ^a   Zhang, Lan ^a   Kleine Brueggeney, Maren ^a   Fimmers, Rolf ^a   Stuber, Frank ^a   Musshoff, Frank ^b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A; ONDANSETRON;

ABDOMINAL SURGERY; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; ENANTIOSELECTIVITY; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; POSTANESTHESIA CARE; PRIORITY JOURNAL; VOMITING;

EID: 79960280142     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e31821d01bc     Document Type: Article

References (36)

1. Macario A, Weinger M, Carney S, Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg 1999;89:652-8 (Pubitemid 29409815)
2. Aapro M. 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology 2005;69:97-109 (Pubitemid 41376907)
3. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496-526 (Pubitemid 350116943)
4. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance. Part I. Clin Pharmacokinet 2009;48: 689-723
5. Candiotti KA, Birnbach DJ, Lubarsky DA, Nhuch F, Kamat A, Koch WH, Nikoloff M, Wu L, Andrews D. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology 2005;102:543-9 (Pubitemid 40315143)
6. Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, Possinger K, Roots I, Brockmoller J. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002;20:2805-11 (Pubitemid 34651509)
7. Janicki PK. Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit 2005;11:RA322-8 (Pubitemid 41482745)
8. Wojnowski L, Kamdem LK. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2006;2:171-82 (Pubitemid 46372363)
9. Crettol S, Venetz JP, Fontana M, Aubert JD, Pascual M, Eap CB. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit 2008;30:689-99
10. Roy JN, Lajoie J, Zijenah LS, Barama A, Poirier C, Ward BJ, Roger M. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 2005;33:884-7 (Pubitemid 41002766)
11. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 2004;26:192-9 (Pubitemid 38501217)
12. Rodriguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 2005;338:299-305 (Pubitemid 41540570)
13. Hesselink DA, van Schaik RH, van der Heiden I, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003;74:245-54 (Pubitemid 37083100)
14. Singh R, Srivastava A, Kapoor R, Sharma K, Mittal D. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. Naunyn Schmiedebergs Arch Pharmacol 2009;380:169-77
15. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors. Part II. Clin Pharmacokinet 2010;49:207-21
16. Pedersen RS, Damkier P, Brosen K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol 2006;62:513-21
17. Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther 2007;82:41-7 (Pubitemid 46944194)
18. Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999;91:693-700 (Pubitemid 29418651)
19. Musshoff F, Madea B, Stuber F, Stamer U. Enantioselective determination of ondansetron and 8-hydroxyondansetron in human plasma of patients recovered from surgery by liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2010;34:581-6
20. Stamer UM, Lehnen K, Hothker F, Bayerer B, Wolf S, Hoeft A, Stuber F. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003;105:231-8 (Pubitemid 37162492)
21. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008;83:234-42
22. Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, Zernak C, Danner K, Jokela R, Pocock SJ, Trenkler S, Kredel M, Biedler A, Sessler DI, Roewer N. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004;350:2441-51
23. Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, Kovac A, Philip BK, Sessler DI, Temo J, Tramer MR, Watcha M. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg 2003;97:62-71 (Pubitemid 36736540)
24. Tramer MR, Reynolds DJ, Moore RA, McQuay HJ. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. Anesthesiology 1997;87:1277-89 (Pubitemid 28007321)
25. Fischer V, Vickers AE, Heitz F, Mahadevan S, Baldeck JP, Minery P, Tynes R. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 1994 22 269-74 (Pubitemid 24099762)
26. Ashforth EI, Palmer JL, Bye A, Bedding A. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. Br J Clin Pharmacol 1994;37:389-91 (Pubitemid 24204604)
27. Corrigan BW, Nicholls B, Thakrar B, Lam R, Grosse C, Alianti J, Palmer JL. Heterogeneity in systemic availability of ondansetron and granisetron following oral administration. Drug Metab Dispos 1999;27:110-2 (Pubitemid 29061009)
28. Liu K, Dai X, Zhong D, Chen X. Quantitative determination of ondansetron in human plasma by enantioselective liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008;864:129-36
29. Shimada T, Aoki Y, Yokogawa K, Nomura M, Ishizaki J, Nishigami J, Miyamoto K. Influence of cytarabine and cyclophosphamide on the disposition kinetics of cyclosporin A after bone marrow transplantation. Transpl Int 2003;16:788-93 (Pubitemid 37509414)
30. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91 (Pubitemid 32268418)
31. Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR, Tarbit MH. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995;23:1225-30
32. Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden I, van Dam T, van der Werf M, Weimar W, Mathot RA. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004;76:545-56 (Pubitemid 39601545)
33. Rodriguez-Antona C, Leskela S, Zajac M, Cuadros M, Alves J, Moneo MV, Martin C, Cigudosa JC, Carnero A, Robledo M, Benitez J, Martinez-Delgado B. Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Blood 2007;110:3345-51 (Pubitemid 350106328)
34. Perera MA. The missing linkage: what pharmacogenetic associations are left to find in CYP3A? Expert Opin Drug Metab Toxicol 2010;6:17-28
35. Villikka K, Kivisto KT, Neuvonen PJ. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther 1999;65:377-81 (Pubitemid 29196539)
36. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmoller J, Halpert JR, Zanger UM, Wojnowski L. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-9 (Pubitemid 33151512)